TW200716152A - Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture - Google Patents

Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture

Info

Publication number
TW200716152A
TW200716152A TW095110860A TW95110860A TW200716152A TW 200716152 A TW200716152 A TW 200716152A TW 095110860 A TW095110860 A TW 095110860A TW 95110860 A TW95110860 A TW 95110860A TW 200716152 A TW200716152 A TW 200716152A
Authority
TW
Taiwan
Prior art keywords
substituted
ethylendiamines
medicaments
manufacture
compound
Prior art date
Application number
TW095110860A
Other languages
English (en)
Chinese (zh)
Inventor
Christian Eickmeier
Stefan Peters
Klaus Fuchs
Niklas Heine
Sandra Handschuh
Cornelia Dorner-Ciossek
Klaus Klinder
Marcus Kostka
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW200716152A publication Critical patent/TW200716152A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
TW095110860A 2005-03-30 2006-03-29 Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture TW200716152A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05006939 2005-03-30

Publications (1)

Publication Number Publication Date
TW200716152A true TW200716152A (en) 2007-05-01

Family

ID=36545049

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095110860A TW200716152A (en) 2005-03-30 2006-03-29 Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture

Country Status (7)

Country Link
US (3) US7713961B2 (enExample)
EP (1) EP1866034A1 (enExample)
JP (1) JP2008534541A (enExample)
AR (1) AR056862A1 (enExample)
CA (1) CA2603404A1 (enExample)
TW (1) TW200716152A (enExample)
WO (1) WO2006103038A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2603404A1 (en) * 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
JP2009503027A (ja) * 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病ｉｉの治療のための置換エタン−１，２−ジアミン
EP1919861A2 (de) * 2005-08-11 2008-05-14 Boehringer Ingelheim International GmbH Verbindungen zur behandlung der alzheimer erkrankung
US20090042867A1 (en) * 2005-08-11 2009-02-12 Klaus Fuchs Compounds for the treatment of alzheimer's disease
EP1915339A1 (de) * 2005-08-11 2008-04-30 Boehringer Ingelheim International GmbH Inhibitoren der beta-sekretase zur behandlung der alzheimer- erkrankung
CA2618474A1 (en) * 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Compounds for treating alzheimer's disease
JP2012505241A (ja) 2008-10-10 2012-03-01 パーデュー・リサーチ・ファウンデーション アルツハイマー病の治療用組成物
EP2376083A4 (en) 2008-11-20 2012-06-20 Purdue Research Foundation QUINAZOLIN-BASED BACE-1 INHIBITORS AND METHODS OF USE
WO2010065861A2 (en) * 2008-12-05 2010-06-10 Purdue Research Foundation Inhibitors of bace 1 and methods for treating alzheimer's disease
JP2013506713A (ja) * 2009-10-05 2013-02-28 コメンティス，インコーポレーテッド β−セクレターゼ活性を阻害するスルホンアミドピロリジン化合物及びその使用方法
US20140066488A1 (en) * 2012-08-30 2014-03-06 Purdue Research Foundation Inhibitors of Memapsin 2 Cleavage for the Treatment of Alzheimer's Disease
US20240383852A1 (en) * 2021-03-12 2024-11-21 Infex Therapeutics Limited Anti-viral compounds
MX2023014754A (es) 2021-06-18 2024-02-12 Aligos Therapeutics Inc Métodos y composiciones dirigidos a pd-l1.
CN119212987A (zh) 2021-12-16 2024-12-27 安力高医药股份有限公司 用于靶向pd-l1的方法和组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ184194A3 (en) 1993-08-09 1995-03-15 Lilly Co Eli Aspartylprotease inhibitor and method of identifying thereof
US7087399B1 (en) 1999-05-13 2006-08-08 Scios, Inc. β-secretase and modulation of β-secretase activity
EP1194449B1 (en) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
CA2449948A1 (en) * 2001-06-08 2002-12-19 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease
EP1453516A2 (de) 2001-10-17 2004-09-08 Boehringer Ingelheim Pharma GmbH & Co.KG 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
AU2003206413A1 (en) * 2002-01-04 2003-07-24 Elan Pharmaceuticals, Inc. Substituted amino carboxamides for the treatment of alzheimer's disease
US7763646B2 (en) * 2002-09-27 2010-07-27 Elan Pharmaceuticals, Inc. Compounds for the treatment of alzheimer's disease
DE60329316D1 (de) * 2002-11-12 2009-10-29 Merck & Co Inc Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
US20050090449A1 (en) 2003-05-13 2005-04-28 Boehringer Ingelheim International Gmbh Novel statine derivatives for the treatment of Alzheimer's disease
JP2007516207A (ja) * 2003-06-30 2007-06-21 メルク　エンド　カムパニー　インコーポレーテッド アルツハイマー病の治療のためのＮ−アルキルフェニルカルボキサミドβ−セクレターゼ阻害剤
EP1750719A2 (en) 2004-05-19 2007-02-14 Boehringer Ingelheim International GmbH Treatment of diseases associated with altered level of amyloid beta peptides
WO2005113582A1 (en) 2004-05-22 2005-12-01 Boehringer Ingelheim International Gmbh Substituted ethane-1,2-diamines for the treatment of alzheimer's disease
WO2006050861A2 (en) 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
WO2006050862A1 (en) 2004-11-10 2006-05-18 Boehringer Ingelheim International Gmbh Statine derivatives for the treatment of alzheimer's disease
CA2603404A1 (en) * 2005-03-30 2006-10-05 Boehringer Ingelheim International Gmbh Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture
JP2009503027A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー病ｉｉの治療のための置換エタン−１，２−ジアミン
US20090042867A1 (en) 2005-08-11 2009-02-12 Klaus Fuchs Compounds for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
EP1866034A1 (en) 2007-12-19
US7713961B2 (en) 2010-05-11
US20060223759A1 (en) 2006-10-05
WO2006103038A1 (en) 2006-10-05
AR056862A1 (es) 2007-10-31
CA2603404A1 (en) 2006-10-05
US20090325940A1 (en) 2009-12-31
US20100204160A1 (en) 2010-08-12
JP2008534541A (ja) 2008-08-28

Similar Documents

Publication Publication Date Title
NL300933I2 (nl) Letermovir
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
EA200401114A3 (ru) Замещённые гидроксиэтиламины
DK1689721T3 (da) Aminopyrazolderivater som GSK-3-ihibitorer
BRPI0412851A (pt) benzamidazóis de n-metila-substituìdos
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
NO20063275L (no) Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom
MX2007003031A (es) Compuestos heteroarilo para uso como betamimeticos en el tratamiento de enfermedades de vias respiratorias.
WO2009007300A3 (en) Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
CY1110401T1 (el) Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων
WO2006055434A3 (en) Macrocyclic tertiary amine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006050861A3 (en) Statine derivatives for the treatment of alzheimer's disease
WO2008023003A8 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
WO2007017511A3 (de) Verbindungen zur behandlung der alzheimer erkrankung
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
MY146802A (en) Novel drugs for treating respiratory diseases
ATE524171T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit
WO2007017510A3 (de) Isophthalsäurediamide zur behandlung der alzheimer erkrankung
ATE407126T1 (de) Herstellung von (s)-4-fluormethyl-dihydro-furan-2-on
TW200800966A (en) Beta-secretase modulators and methods of use
MX2010004318A (es) Moduladores de la gamma-secretasa con enlaces de amina.